NovaBridge Biosciences
NBP
$3.89
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 12/31/2024 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.76% | -68.00% | 3.94% | 3.94% | 12.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.58% | -58.49% | 0.71% | 0.71% | -6.51% |
| Operating Income | 27.58% | 58.49% | -1.94% | -1.94% | 5.37% |
| Income Before Tax | 66.68% | 38.44% | 67.50% | 67.50% | 38.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 66.68% | 38.44% | 67.50% | 67.50% | 38.59% |
| Earnings from Discontinued Operations | -- | -- | 106.27% | 106.27% | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.68% | -121.65% | 85.34% | 85.34% | 66.84% |
| EBIT | 27.58% | 58.49% | -1.94% | -1.94% | 5.37% |
| EBITDA | 27.60% | 58.33% | -2.37% | -2.37% | 5.15% |
| EPS Basic | 73.94% | -121.46% | 85.01% | 85.01% | 66.12% |
| Normalized Basic EPS | 22.24% | 38.99% | 55.12% | 55.12% | 67.93% |
| EPS Diluted | 73.94% | -121.46% | 85.01% | 85.01% | 66.12% |
| Normalized Diluted EPS | 22.24% | 38.99% | 55.12% | 55.12% | 67.93% |
| Average Basic Shares Outstanding | 27.87% | 0.95% | -2.12% | -2.12% | -2.13% |
| Average Diluted Shares Outstanding | 27.87% | 0.95% | -2.12% | -2.12% | -2.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |